A	B	C
1	Main
2		Brand	Lynparza, fka AZD2281
3		Generic	olaparib
4		MOA	PARP1 inhibitor
5		Indication	aOC, mCRPC, pancreatic, mBC
6		Economics	MRK. Originally from KuDOS, acquired by AZN in 2006
7		PK	LogP=1.9, MW=434, HBD=1, HBA=5, RB=4, TPSA=82. Capsule discontinued, Tablet replaced
8		IP	7151102 first patent doesn't correspond to structure, expired
9			7449464 expires 2024
10			8071579 expires 2027, MOU patent
11			8143241 expires 2027, MOU patent
12			8475842 expires 2029, formulation patent
13			8859562 expires 2031, ridiculous claim
14
15		Clinical Trials
16			Phase III SOLO-2 - NCT01874353
17
18			Phase III POLO
19
20			Phase III "SOLO-1" n=391 1L aOC BRCA+ in PR/CR - NEJM 2018, NCT01844986
21			HR=0.30 TTP/OS
22
23			Phase III "PROpel" 1L CRPC abiraterone+-olaparib - NEJM 2022, NCT03732820
24			mibPFS HR=0.66, OS=0.86 (p=0.29 immature)
25			24.8 months vs. 16.6 months mibPFS